Adma Biologics, Inc. (ADMA) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Adma Biologics’s revenue went from $11M in fiscal 2016 to $510M in fiscal 2025, growth of about 53.7% a year.
Net income in fiscal 2025 was $147M, a net margin of 28.8%; the best year in this period was 2024 with $198M.
Over the twelve months to September 30, 2026, revenue was $519M and net income $182M.
Free cash flow was $28M in fiscal 2025 and positive in 3 of the 10 years shown.
The diluted share count rose 1915% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $519M | $510M | $426M | $258M | $154M | $81M | $42M | $29M | $17M | $23M | $11M |
| Gross profit | $356M | $293M | $220M | $89M | $35M | $1M | -$19M | -$10M | -$25M | -$6M | $4M |
| Operating income | $241M | $191M | $139M | $22M | -$39M | -$58M | -$65M | -$41M | -$60M | -$39M | -$17M |
| Net income | $182M | $147M | $198M | -$28M | -$66M | -$72M | -$76M | -$48M | -$66M | -$44M | -$20M |
| EPS (diluted) | $0.77 | $0.60 | $0.81 | $-0.13 | $-0.33 | $-0.51 | $-0.88 | $-0.89 | $-1.45 | $-1.91 | $-1.61 |
| R&D | $14M | $5M | $2M | $3M | $4M | $4M | $6M | $2M | $4M | $6M | $8M |
| Revenue growth | — | +19.6% | +65.1% | +67.6% | +90.4% | +91.7% | +43.9% | +72.8% | −25.4% | +113.5% | +48.5% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $141M | $50M | $119M | $9M | -$60M | -$112M | -$102M | -$76M | -$63M | -$37M | -$18M |
| Capital spending | -$8M | -$23M | -$8M | -$5M | -$14M | -$14M | -$13M | -$4M | -$2M | -$3M | -$73410 |
| Free cash flow | $133M | $28M | $110M | $4M | -$73M | -$126M | -$115M | -$80M | -$65M | -$40M | -$18M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | $189M | $32M | $0 | $0 | — | — | — | — | — | — | — |
| Stock-based pay | $24M | $20M | $14M | $6M | $5M | $3M | $3M | $3M | $2M | $2M | $1M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $88M | $103M | $51M | $87M | $51M | $56M | $27M | $27M | $43M | $15M |
| Debt | — | $80M | $82M | $141M | $154M | $103M | $105M | $70M | $26M | $25M | $18M |
| Equity | — | $477M | $349M | $135M | $152M | $141M | $88M | $26M | $20M | $40M | -$4M |
| Total assets | — | $624M | $489M | $329M | $348M | $276M | $208M | $127M | $89M | $108M | $24M |
| Shares (diluted) | 226M | 245M | 243M | 224M | 198M | 140M | 86M | 54M | 45M | 23M | 12M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 68.5% | 57.4% | 51.5% | 34.4% | 22.9% | 1.5% | -45.2% | -34.6% | -148.4% | -28.1% | 40.3% |
| Operating margin | 46.5% | 37.5% | 32.6% | 8.4% | -25.6% | -72.1% | -153.8% | -141.1% | -354.9% | -172.7% | -162.6% |
| Net margin | 35.1% | 28.8% | 46.4% | -10.9% | -42.8% | -88.5% | -179.4% | -164.5% | -387.1% | -192.3% | -183.1% |
| FCF margin | 25.6% | 5.5% | 25.9% | 1.6% | -47.6% | -155.5% | -271.7% | -272.6% | -381.4% | -175.5% | -172.0% |
| ROIC | — | 27.6% | 25.5% | 7.8% | -12.8% | -18.9% | -26.6% | -34.1% | -103.1% | -47.3% | -124.0% |
| ROE | — | 30.8% | 56.6% | -20.9% | -43.4% | -50.7% | -85.8% | -184.3% | -332.5% | -108.5% | 437.8% |
Frequently asked questions
What is Adma Biologics’s annual revenue?
$510M in fiscal 2025 and $519M over the twelve months to September 30, 2026.
How much profit does Adma Biologics make?
Net income was $147M in fiscal 2025 (net margin 28.8%).
Is Adma Biologics’s revenue growing?
Yes: revenue rose 19.6% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.